To complement its MR-guided AI-assisted scanning expertise with analysis and reporting in neurological disease assessment, GE HealthCare expects to integrate the icometrix icobrain platform with its MRI systems for seamless workflow. With approvals of new anti-amyloid therapies continuing to increase globally to treat the disease, the demand for more frequent neurological MRI exams also continues to grow. This product suite also features a strong pipeline of clinical decision support applications in development to improve neurological care in the future. icobrain extracts key data from brain MRI scans, facilitating more accurate diagnoses and personalized treatment plans across hospitals globally. GE HealthCare intends to fund this transaction with cash on hand.